Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists
Brad R. Henke, Christopher J. Aquino, Larry S. Birkemo et al. · Journal of Medicinal Chemistry · 1997
We previously described a series of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepine CCK-A agonists exemplified by compound 1 (GW 5823), which is the first reported binding selective CCK-A full agonist demonstrating oral efficacy in a rat feeding model. In this report we describe analogs of compound 1 designed to explore changes to the C3 and N1 pharmacophores and their effect on agonist activity and receptor selectivity. Agonist efficacy in this series was affected by stereoelectronic factors within the C3 moiety. Binding affinity for the CCK-A vs CCK-B receptor showed little dependence on the structure of the C3 moiety but was affected by the nature of the second substituent at C3. Structure-activity relationships at the N1-anilidoacetamide "trigger" moiety within the C3 indazole series were also investigated. Both agonist efficacy and binding affinity within this series were modulated by variation of substituents on the N1-anilidoacetamide moiety. Evaluation of several analogs in an vivo mouse gallbladder emptying assay revealed compound 1 to be the most potent and efficacious of all the analogs tested. The pharmacokinetic and pharmacodynamic profile of 1 in rats is also discussed.
Cited by 85 works. doi:10.1021/jm970265x
Authors
- Brad R. Henke
- Christopher J. Aquino
- Larry S. Birkemo
- Dallas K. Croom
- Gregory N. Ervin
- Mary K. Grizzle
- Gavin C. Hirst
- Michael K. James
- Michael F. Johnson
- Kennedy L. Queen
- Ronald G. Sherrill
- Elizabeth E. Sugg
- Edward M. Suh
- Jerzy Szewczyk
- Rayomand J. Unwalla
- Jeff Yingling
- Timothy Mark Willson
References
- Rapid chromatographic technique for preparative separations with moderate resolution
- Protective groups in organic synthesis
- Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists
- C-terminal octapeptide of cholecystokinin decreases food intake in man
- Obesity: Theory and Therapy
- Cloning of Shiga-like toxin structural genes from a toxin converting phage of Escherichia coli
- A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus
- Molecular cloning of the human brain and gastric cholecystokinin receptor: Structure, functional expression and chromosomal localization
- Classification and function of CCK receptors
- Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.